首页> 外文期刊>Journal of Medical Genetics and Genomics >A study of correlation between CYP2C9 gene polymorphism and Warfarin maintenance dose in anticoagulant therapy among Han people in Yunnan of China
【24h】

A study of correlation between CYP2C9 gene polymorphism and Warfarin maintenance dose in anticoagulant therapy among Han people in Yunnan of China

机译:CYP2C9基因多态性与华法林维持剂量在云南汉族人群抗凝治疗中的相关性研究

获取原文
           

摘要

In this study, we investigated the correlation between CYP2C9 gene polymorphism and maintenance dose of Warfarin in 300 patients who were the Han population derived from the Affiliated Yan An Hospital of Kunming Medical University in Yunnan Province of China, subjected to the operation of cardiac valve replacement and Warfarin oral administration post operation from 2008 to 2009 by detecting the genotypes and Allele Frequency at the three candidate loci (CYP2C9*2,CYP2C9*3 and CYP2C9*c_65) of CYP2C9 gene from the blood samples. Polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) assay and DNA sequencing were used to ascertain the genotypes and their corresponding distribution rate. The maintenance dose of Warfarin administered in anticoagulant therapy among the CYP2C9*3 genetypes found in our experiment showed: A/A wild type > A/C heterozygote>C/C homozygote, suggesting that patients with C mutation need the lowest maintenance dose of Warfarin among the three genotypes found in this study. Our results will shed a new light on the personalized medicine of Warfarin and provide basic and genetic experimental data and foundation for future studies with regard to multiple genes’ effect on Warfarin dorsage in anticogulantant therapy.
机译:在这项研究中,我们调查了CYP2C9基因多态性与华法林维持剂量之间的相关性,该患者来自中国云南省昆明医科大学附属延安医院的300例汉族人,他们接受了心脏瓣膜置换手术并于2008年至2009年术后口服华法林,通过从血样中检测CYP2C9基因的三个候选位点(CYP2C9 * 2,CYP2C9 * 3和CYP2C9 * c_65)的基因型和等位基因频率。用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析和DNA测序来确定基因型及其相应的分布率。在我们的实验中发现的CYP2C9 * 3基因型中,在抗凝治疗中给予华法林维持剂量为:A / A野生型> A / C杂合子> C / C纯合子,表明具有C突变的患者需要最低的华法林维持剂量在这项研究中发现的三种基因型中。我们的研究结果将为华法林的个性化治疗提供新的思路,并为基础的基因研究和遗传学实验数据,以及未来有关抗凝治疗中多个基因对华法林背负效应的研究提供基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号